{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T19:24:44Z","timestamp":1794252284526,"version":"4.9.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41571-024-00948-1","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T14:02:25Z","timestamp":1728050545000},"page":"888-899","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The high costs of anticancer therapies in the USA: challenges, opportunities and progress"],"prefix":"10.1038","volume":"21","author":[{"given":"Shelley A.","family":"Jazowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6725-7634","authenticated-orcid":false,"given":"Rahul K.","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3907-9196","authenticated-orcid":false,"given":"Stacie B.","family":"Dusetzina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"948_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40273-023-01320-4","volume":"42","author":"DT Michaeli","year":"2024","unstructured":"Michaeli, D. T. & Michaeli, T. Launch and post-launch prices of injectable cancer drugs in the US: clinical benefit, innovation, epidemiology, and competition. Pharmacoeconomics 42, 117\u2013131 (2024).","journal-title":"Pharmacoeconomics"},{"key":"948_CR2","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.jval.2023.06.020","volume":"26","author":"DT Michaeli","year":"2023","unstructured":"Michaeli, D. T. & Michaeli, T. Cancer drug prices in the United States: efficacy, innovation, clinical trial evidence, and epidemiology. Value Health 26, 1590\u20131600 (2023).","journal-title":"Value Health"},{"key":"948_CR3","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1001\/jama.2022.5542","volume":"327","author":"BN Rome","year":"2022","unstructured":"Rome, B. N., Egilman, A. C. & Kesseslheim, A. S. Trends in prescription drug launch prices. JAMA 327, 2145\u20132147 (2022).","journal-title":"JAMA"},{"key":"948_CR4","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1377\/hlthaff.2015.1145","volume":"35","author":"CS Bennette","year":"2016","unstructured":"Bennette, C. S., Richards, C., Sullivan, S. D. & Ramsey, S. D. Steady increase in prices for oral anticancer drugs after market launch suggest a lack of competitive pressure. Health Aff. 35, 805\u2013812 (2016).","journal-title":"Health Aff."},{"key":"948_CR5","unstructured":"Rind, D. et al. Unsupported prices increase report: unsupported price increases occurring in 2022. Institute for Clinical and Economic Review icer.org\/wp-content\/uploads\/2023\/04\/UPI_2023_Report_121123.pdf (2023)."},{"key":"948_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.15720","volume":"5","author":"SA Jazowski","year":"2022","unstructured":"Jazowski, S. A., Wilson, L., Dusetzina, S. B., Zafar, S. Y. & Zullig, L. L. Association of high-deductible health plan enrollment with spending on and use of lenalidomide therapy among commercially insured patients with multiple myeloma. JAMA Netw. Open. 5, e2215720 (2022).","journal-title":"JAMA Netw. Open."},{"key":"948_CR7","unstructured":"McAuliff, M. Sky-high drug prices driven by pharma profits, House Dems charge. KFF Health News kffhealthnews.org\/news\/sky-high-drug-prices-driven-by-pharma-profits-house-dems-charge\/ (2020)."},{"key":"948_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1200\/JCO.2016.72.2124","volume":"36","author":"N Gordon","year":"2018","unstructured":"Gordon, N., Stemmer, S. M., Greenberg, D. & Goldstein, D. A. Trajectories of injectable cancer drug costs after launch in the United States. J. Clin. Oncol. 36, 319\u2013325 (2018).","journal-title":"J. Clin. Oncol."},{"key":"948_CR9","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1001\/jama.2016.11237","volume":"316","author":"AS Kesselheim","year":"2016","unstructured":"Kesselheim, A. S., Avorn, J. & Sarpatwari, A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA 316, 858\u2013871 (2016).","journal-title":"JAMA"},{"key":"948_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.4801","volume":"3","author":"KN Vokinger","year":"2022","unstructured":"Vokinger, K. N. & Naci, H. Negotiating drug prices in the US \u2013 lessons from Europe. JAMA Health Forum 3, e224801 (2022).","journal-title":"JAMA Health Forum"},{"key":"948_CR11","unstructured":"Mulcahy, A. W. et al. International Prescription Drug Price Comparisons (RAND, 2021)."},{"key":"948_CR12","unstructured":"Peter G. Peterson Foundation. How Much Does the United States Spend on Prescription Drugs Compared to Other Countries? (Peter G. Peterson Foundation, 2022)."},{"key":"948_CR13","unstructured":"IQVIA. Global Oncology Trends 2023 (IQVIA, 2023)."},{"key":"948_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2026","volume":"7","author":"KN Vokinger","year":"2021","unstructured":"Vokinger, K. N. et al. Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe. JAMA Oncol. 7, e212026 (2021).","journal-title":"JAMA Oncol."},{"key":"948_CR15","unstructured":"Goldstein, A. House Democrats find in three-year investigation that drug prices are \u2018unsustainable, unjustifiable and unfair.' Washington Post www.washingtonpost.com\/health\/2021\/12\/10\/house-democrats-find-three-year-investigation-that-drug-prices-are-unsustainable-unjustifiable-unfair\/ (2021)."},{"key":"948_CR16","unstructured":"Shmerling, R. H. Why Do Your Prescription Drugs Cost So Much? (Harvard Health Publishing, 2024)."},{"key":"948_CR17","unstructured":"PDQ\u00ae Adult Treatment Editorial Board. Financial Toxicity and Cancer Treatment (PDQ\u00ae) \u2013 Health Professional Version (National Cancer Institute, 2024)."},{"key":"948_CR18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1200\/JCO.2017.74.5091","volume":"36","author":"JA Doshi","year":"2018","unstructured":"Doshi, J. A., Li, P., Huo, H., Pettit, A. R. & Armstrong, K. A. Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents. J. Clin. Oncol. 36, 476\u2013482 (2018).","journal-title":"J. Clin. Oncol."},{"key":"948_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1377\/hlthaff.2021.01742","volume":"41","author":"SB Dusetzina","year":"2022","unstructured":"Dusetzina, S. B. et al. Many Medicare beneficiaries do not fill high-price specialty drug prescriptions. Health Aff. 41, 487\u2013496 (2022).","journal-title":"Health Aff."},{"key":"948_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","volume":"32","author":"SB Dusetzina","year":"2014","unstructured":"Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A. & Keating, N. L. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J. Clin. Oncol. 32, 306\u2013311 (2014).","journal-title":"J. Clin. Oncol."},{"key":"948_CR21","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1200\/JOP.2017.027136","volume":"14","author":"J Park","year":"2018","unstructured":"Park, J. & Look, K. A. Relationship between objective financial burden and the health-related quality of life and mental health of patients with cancer. J. Oncol. Pract. 14, e113\u2013e121 (2018).","journal-title":"J. Oncol. Pract."},{"key":"948_CR22","doi-asserted-by":"publisher","first-page":"dw205","DOI":"10.1093\/jnci\/djw205","volume":"109","author":"CK Altice","year":"2016","unstructured":"Altice, C. K., Banegas, M. P., Tucker-Seeley, R. D. & Yabroff, K. R. Financial hardships experienced by cancer survivors: a systematic review. J. Natl Cancer Inst. 109, dw205 (2016).","journal-title":"J. Natl Cancer Inst."},{"key":"948_CR23","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1002\/cncr.28262","volume":"119","author":"EE Kent","year":"2013","unstructured":"Kent, E. E. et al. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer 119, 3710\u20133717 (2013).","journal-title":"Cancer"},{"key":"948_CR24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","volume":"18","author":"SY Zafar","year":"2013","unstructured":"Zafar, S. Y. et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient\u2019s experience. Oncologist 18, 381\u2013390 (2013).","journal-title":"Oncologist"},{"key":"948_CR25","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1056\/NEJMsa1910366","volume":"383","author":"K Yeung","year":"2020","unstructured":"Yeung, K., Barthold, D., Dusetzina, S. B. & Basu, A. Patient and plan spending after state specialty-drug out-of-pocket spending caps. N. Engl. J. Med. 383, 558\u2013566 (2020).","journal-title":"N. Engl. J. Med."},{"key":"948_CR26","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1377\/hlthaff.2018.05476","volume":"38","author":"SB Dusetzina","year":"2019","unstructured":"Dusetzina, S. B., Jazowski, S., Cole, A. & Nguyen, J. Sending the wrong price signal: why do some brand-name drugs cost Medicare beneficiaries less than generics? Health Aff. 38, 1188\u20131194 (2019).","journal-title":"Health Aff."},{"key":"948_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3598","volume":"4","author":"SB Dusetzina","year":"2018","unstructured":"Dusetzina, S. B., Huskamp, H. A., Winn, A. N., Basch, E. & Keating, N. L. Out-of-pocket and health care spending changes for patients using orally administered anticancer therapy after adoption of state parity laws. JAMA Oncol. 4, e173598 (2018).","journal-title":"JAMA Oncol."},{"key":"948_CR28","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/jnci\/djz243","volume":"112","author":"SB Dusetzina","year":"2020","unstructured":"Dusetzina, S. B. et al. Oral oncology parity laws, medication use, and out-of-pocket spending for patients with blood cancers. J. Natl Cancer Inst. 112, 1055\u20131062 (2020).","journal-title":"J. Natl Cancer Inst."},{"key":"948_CR29","first-page":"554","volume":"27","author":"A Spargo","year":"2021","unstructured":"Spargo, A. et al. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia. J. Manag. Care Spec. Pharm. 27, 554\u2013564 (2021).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"948_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/cncr.31910","volume":"125","author":"AL Chin","year":"2019","unstructured":"Chin, A. L., Bentley, J. P. & Pollom, E. L. The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer. Cancer 125, 374\u2013381 (2019).","journal-title":"Cancer"},{"key":"948_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.0673","volume":"2","author":"SB Dusetzina","year":"2021","unstructured":"Dusetzina, S. B. et al. Comparison of anticancer medication use and spending under US oncology parity laws with and without out-of-pocket spending caps. JAMA Health Forum 2, e210673 (2021).","journal-title":"JAMA Health Forum"},{"key":"948_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jval.2015.10.005","volume":"19","author":"SM Kirchner","year":"2016","unstructured":"Kirchner, S. M. et al. The parity paradigm: can legislation help reduce the cost burden of oral anticancer medications? Value Health 19, 88\u201399 (2016).","journal-title":"Value Health"},{"key":"948_CR33","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrclinonc.2017.31","volume":"14","author":"V Prasad","year":"2017","unstructured":"Prasad, V., Jesus, K.De & Mailankody, S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat. Rev. Clin. Oncol. 14, 381\u2013390 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"948_CR34","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMp1500848","volume":"372","author":"J Avorn","year":"2015","unstructured":"Avorn, J. The $2.6 billion pill \u2013 methodologic and policy considerations. N. Engl. J. Med. 372, 1877\u20131879 (2015).","journal-title":"N. Engl. J. Med."},{"key":"948_CR35","unstructured":"Butler, J. Drug Price Transparency Laws Position States to Impact Drug Prices (National Academy for State Health Policy, 2022)."},{"key":"948_CR36","unstructured":"National Academy for State Health Policy. What are we Learning From State Reporting on Drug Pricing? (National Academy for State Health Policy, 2019)."},{"key":"948_CR37","unstructured":"Clark, B. & Puthiyath M. S. Can State Prescription Drug Affordability Boards Address High-cost Drug Prices? (The Commonwealth Fund, 2022)."},{"key":"948_CR38","unstructured":"Becker, C. Digging into prescription drug data: affordability boards and transparency. National Conference of State Legislatures www.ncsl.org\/health\/digging-into-prescription-drug-data-affordability-boards-and-transparency (2022)."},{"key":"948_CR39","unstructured":"Holcombe, D. Prescription Drug Affordability Boards and Drug Importation \u2013 at or coming to a state near you? (Oncology Practice Management, 2024)."},{"key":"948_CR40","unstructured":"Feldman, M. A. Prescription Drug Affordability Boards: Another Quick Fix with Unintended Consequences? (MDedge, 2023)."},{"key":"948_CR41","unstructured":"Community Oncology Alliance. COA Position Statement on Prescription Drug Affordability Boards (Community Oncology Alliance, 2023)."},{"key":"948_CR42","unstructured":"Wingerter, M. Enbrel drugmaker sues over Colorado\u2019s potential price cap, says prescription drug board is unconstitutional. The Denver Post www.denverpost.com\/2024\/03\/26\/amgen-sues-colorado-prescription-drug-affordability-board-enbrel-price-cap\/#:~:Text=The%20lawsuit%2C%20filed%20in%20U.S.,be%20overturned%20by%20the%20courts (2024)."},{"key":"948_CR43","unstructured":"Gudiksen, K. L., Chang, S. M. & King, J. S. Navigating Legal Challenges to State Efforts to Control Drug Prices: Pharmacy Benefit Manager Regulation, Price Gouging, and Price Transparency (National Academy for State Health Policy, 2019)."},{"key":"948_CR44","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.12104","volume":"2","author":"MS Ryan","year":"2019","unstructured":"Ryan, M. S. & Sood, N. Analysis of state-level drug pricing transparency laws in the United States. JAMA Netw. Open. 2, e1912104 (2019).","journal-title":"JAMA Netw. Open."},{"key":"948_CR45","unstructured":"Baldwin, Braun lead bill to require transparency for skyrocketing drug prices. Tammy Baldwin: United States Senator for Wisconsin www.baldwin.senate.gov\/news\/press-releases\/baldwin-braun-lead-bill-to-require-transparency-for-skyrocketing-drug-prices (2023)."},{"key":"948_CR46","unstructured":"Grassley, Cantwell introduce bipartisan bill to combat rising prescription drug prices and provide more transparency. Chuck Grassley www.grassley.senate.gov\/news\/news-releases\/grassley-cantwell-introduce-bipartisan-bill-to-combat-rising-prescription-drug-prices-and-provide-more-transparency (2022)."},{"key":"948_CR47","unstructured":"Cubanski, J., Neuman, T. & Freed, M. Explaining the Prescription Drug Provisions in the Inflation Reduction Act (Kaiser Family Foundation, 2023)."},{"key":"948_CR48","first-page":"762","volume":"30","author":"I Hernandez","year":"2024","unstructured":"Hernandez, I. et al. Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives. J. Manag. Care Spec. Pharm. 30, 762\u2013772 (2024).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"948_CR49","unstructured":"Medicare Drug Price Negotiation Program. Fact sheet: key information on the process for the first round of negotiations for the Medicare Drug Price Negotiation Program. Centers for Medicare & Medicaid Services www.cms.gov\/files\/document\/fact-sheet-negotiation-process-flow.pdf (2023)."},{"key":"948_CR50","unstructured":"Gardner, L. Drugmakers, trade groups push back against Medicare drug price negotiations. Politico www.politico.com\/news\/2023\/08\/29\/drugmakers-trade-groups-push-back-against-medicare-drug-price-negotiations-00111936 (2023)."},{"key":"948_CR51","unstructured":"Baron, Z. & Twinamatsiko, A. A deep dive into takings clause challenges to the Medicare Drug Price Negotiation Program. Health Affairs www.healthaffairs.org\/content\/forefront\/deep-dive-into-takings-clause-challenges-medicare-drug-price-negotiation-program (2023)."},{"key":"948_CR52","unstructured":"Ranganathan, S. & Baron, Z. Another administration win in Medicare drug price negotiation lawsuits. Health Affairs www.healthaffairs.org\/content\/forefront\/another-administration-win-medicare-drug-price-negotiation-lawsuits (2024)."},{"key":"948_CR53","unstructured":"Briefing Room. Fact Sheet: Biden-Harris administration announces new, lower prices for first ten drugs selected for Medicare price negotiation to lower costs for millions of Americans. The White House www.whitehouse.gov\/briefing-room\/statements-releases\/2024\/08\/15\/fact-sheet-biden-harris-administration-announces-new-lower-prices-for-first-ten-drugs-selected-for-medicare-price-negotiation-to-lower-costs-for-millions-of-americans\/ (2024)."},{"key":"948_CR54","unstructured":"Levitt, L. The 4 arguments you will hear against drug price negotiation. The New York Times www.nytimes.com\/2023\/09\/06\/opinion\/medicare-drug-price-negotiation.html (2023)."},{"key":"948_CR55","unstructured":"Goldman, D. et al. Mitigating the Inflation Reduction Act\u2019s adverse impacts on the prescription drug market. USC Schaeffer healthpolicy.usc.edu\/research\/mitigating-the-inflation-reduction-acts-potential-adverse-impacts-on-the-prescription-drug-market\/ (2023)."},{"key":"948_CR56","unstructured":"Tong, N. Pharmaceutical industry rips \u2018draconian\u2019 price negotiation provision. Fierce Healthcare www.fiercehealthcare.com\/payers\/pharmaceutical-industry-rips-draconian-price-negotiation-provision (2023)."},{"key":"948_CR57","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jpubeco.2012.10.003","volume":"97","author":"ME Blume-Kohout","year":"2013","unstructured":"Blume-Kohout, M. E. & Sood, N. Market size and innovation: effects of Medicare Part D on pharmaceutical research and development. J. Public. Econ. 97, 327\u2013336 (2013).","journal-title":"J. Public. Econ."},{"key":"948_CR58","doi-asserted-by":"crossref","unstructured":"Dranove, D. Garthwaite, C. & Hermosilla, M. Pharmaceutical profits and the social value of innovation. Kellogg School of Management www.kellogg.northwestern.edu\/faculty\/garthwaite\/htm\/medicare_pharma_innovation.pdf (2014).","DOI":"10.3386\/w20212"},{"key":"948_CR59","unstructured":"Skovronsky, D. M. The IRA\u2019s nonsensical distinction between small- and large-molecule drugs. STAT www.statnews.com\/2023\/05\/09\/ira-inflation-reduction-act-small-large-molecule-drugs\/ (2023)."},{"key":"948_CR60","unstructured":"Liu, A. Lilly exec blasts IRA\u2019s \u2018nonsensical\u2019 distinctions as pharma readies legal attacks elsewhere. Fierce Pharma www.fiercepharma.com\/pharma\/lilly-exec-blasts-iras-nonsensical-chemical-biologics-disparity-drugmakers-ready-legal (2023)."},{"key":"948_CR61","unstructured":"Pew Charitable Trust. Policy proposal: reducing the exclusivity period for biological products. Pew www.pewtrusts.org\/en\/research-and-analysis\/fact-sheets\/2017\/09\/policy-proposal-reducing-the-exclusivity-period-for-biological-products (2017)."},{"key":"948_CR62","unstructured":"Stanford, J. The IRA is already curtailing small molecule drug development. Here\u2019s how to reverse that. BioSpace www.biospace.com\/the-ira-is-already-curtailing-small-molecule-drug-development-here-s-how-to-reverse-that (2024)."},{"key":"948_CR63","unstructured":"Slabodkin, G. IRA drives Pfizer\u2019s decision to focus on biologics, not small molecules. BioSpace www.biospace.com\/ira-drives-pfizer-s-decision-to-focus-on-biologics-not-small-molecules#:~:Text=Pfizer%20executives%20said%20the%20company\u2019s,explained%20at%20last%20week\u2019s%20meeting (2024)."},{"key":"948_CR64","unstructured":"Beasley, D. US will still pay at least twice as much after negotiating drug prices. Reuters www.reuters.com\/world\/us\/us-will-still-pay-least-twice-much-after-negotiating-drug-prices-2024-09-03\/ (2024)."},{"key":"948_CR65","doi-asserted-by":"crossref","unstructured":"Walrath, R. Lawmakers introduce bill to fix the Inflation Reduction Act's \u2018small-molecule penalty\u2019. Chemical & Engineering News cen.acs.org\/policy\/legislation-\/Lawmakers-introduce-bill-fix-Inflation\/102\/web\/2024\/02 (2024).","DOI":"10.1021\/cen-10205-polcon1"},{"key":"948_CR66","unstructured":"Murphy introduces legislation to eliminate IRA \u201cpill penalty\u201d and support small molecule drug innovation. U.S. Congressman Gregory F. Murphy, M.D. murphy.house.gov\/media\/press-releases\/murphy-introduces-legislation-eliminate-ira-pill-penalty-and-support-small (2024)."},{"key":"948_CR67","unstructured":"Cubanski, J. & Neuman, T. Prices increased faster than inflation for half of all drugs covered by Medicare in 2020. Kaiser Family Foundation www.kff.org\/medicare\/issue-brief\/prices-increased-faster-than-inflation-for-half-of-all-drugs-covered-by-medicare-in-2020\/ (2022)."},{"key":"948_CR68","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1001\/jama.2019.4492","volume":"321","author":"SB Dusetzina","year":"2019","unstructured":"Dusetzina, S. B., Huskamp, H. A. & Keating, N. L. Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare Part D, 2010 to 2019. JAMA 321, 2025\u20132028 (2019).","journal-title":"JAMA"},{"key":"948_CR69","unstructured":"US Department of Health and Human Services. HHS announces cost savings for 64 prescription drugs thanks to Medicare rebate program established by the Biden-Harris administration\u2019s lower cost prescription drug law. HHS www.hhs.gov\/about\/news\/2024\/06\/26\/hhs-announces-cost-savings-64-prescription-drugs-thanks-medicare-rebate-program-established-biden-harris-administrations-lower-cost-prescription-drug-law.html (2024)."},{"key":"948_CR70","unstructured":"Congressional Budget Office. How CBO estimated the budgetary impact of key prescription drug provisions in the 2022 Reconciliation Act. Congressional Budget Office www.cbo.gov\/system\/files\/2023-02\/58850-IRA-Drug-Provs.pdf?utm_campaign=20230228BIEM_AT_CBO%20Report%20on%20IRA&utm_medium=email&utm_source=Eloqua (2023)."},{"key":"948_CR71","unstructured":"Beasley, D. Prices for new US drugs rose 35% in 2023, more than the previous year. Reuters www.reuters.com\/business\/healthcare-pharmaceuticals\/prices-new-us-drugs-rose-35-2023-more-than-previous-year-2024-02-23\/ (2024)."},{"key":"948_CR72","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1001\/jamaoncol.2021.5433","volume":"8","author":"TJ Hwang","year":"2022","unstructured":"Hwang, T. J., Qin, X., Keating, N. L., Huskamp, H. A. & Dusetzina, S. B. Assessment of out-of-pocket costs with rebate pass-through for brand-name cancer drugs under Medicare Part D. JAMA Oncol. 8, 155\u2013156 (2022).","journal-title":"JAMA Oncol."},{"key":"948_CR73","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.2019.7521","volume":"322","author":"TJ Hwang","year":"2019","unstructured":"Hwang, T. J., Dusetzina, S. B., Feng, J., Maini, L. & Kesselheim, A. S. Price increases of protected-class drugs in Medicare Part D, relative to inflation, 2012-2017. JAMA 322, 267\u2013269 (2019).","journal-title":"JAMA"},{"key":"948_CR74","unstructured":"Center for Medicare. 2023 Medicare Part D low income subsidy income and resource standards. Centers for Medicare & Medicaid Services www.cms.gov\/files\/document\/2023medicarepartdlowincomesubsidylisincomeandresourcestandardsg.pdf (2023)."},{"key":"948_CR75","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/jnci\/djz183","volume":"112","author":"YT Chou","year":"2020","unstructured":"Chou, Y. T. et al. The association between Medicare low-income subsidy and anticancer treatment uptake in advanced lung cancer. J. Natl Cancer Inst. 112, 637\u2013646 (2020).","journal-title":"J. Natl Cancer Inst."},{"key":"948_CR76","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1200\/JCO.2016.67.3350","volume":"34","author":"A Biggers","year":"2016","unstructured":"Biggers, A. et al. Medicare D subsidies and racial disparities in persistence and adherence with hormonal therapy. J. Clin. Oncol. 34, 4398\u20134404 (2016).","journal-title":"J. Clin. Oncol."},{"key":"948_CR77","doi-asserted-by":"publisher","first-page":"djv130","DOI":"10.1093\/jnci\/djv130","volume":"107","author":"JM Neuner","year":"2015","unstructured":"Neuner, J. M. et al. The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees. J. Natl Cancer Inst. 107, djv130 (2015).","journal-title":"J. Natl Cancer Inst."},{"key":"948_CR78","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1200\/JCO.2016.67.4184","volume":"34","author":"AN Winn","year":"2016","unstructured":"Winn, A. N., Keating, N. L. & Dusetzina, S. B. Factors associated with tyrosine kinase inhibitor initiation and adherence among Medicare beneficiaries with chronic myeloid leukemia. J. Clin. Oncol. 34, 4323\u20134328 (2016).","journal-title":"J. Clin. Oncol."},{"key":"948_CR79","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1080\/19371918.2018.1462285","volume":"33","author":"L Bakk","year":"2018","unstructured":"Bakk, L. & Cadet, T. J. Awareness of the Medicare Part D low-income subsidy among older non-Hispanic blacks and Hispanics. Soc. Work. Public. Health 33, 250\u2013258 (2018).","journal-title":"Soc. Work. Public. Health"},{"key":"948_CR80","unstructured":"Reichard, J. Panel: problems persist in Medicare\u2019s low-income drug benefit. The Commonwealth Fund www.commonwealthfund.org\/publications\/newsletter-article\/panel-problems-persist-medicares-low-income-drug-benefit (2024)."},{"key":"948_CR81","doi-asserted-by":"publisher","first-page":"246","DOI":"10.37765\/ajmc.2023.89357","volume":"29","author":"SA Jazowski","year":"2023","unstructured":"Jazowski, S. A. et al. Association between low-income subsidies and inequities in orally administered antimyeloma therapy use. Am. J. Manag. Care 29, 246\u2013254 (2023).","journal-title":"Am. J. Manag. Care"},{"key":"948_CR82","unstructured":"Cubanski, J. & Neuman, T. Changes to Medicare Part D in 2024 and 2025 under the Inflation Reduction Act and how enrollees will benefit. Kaiser Family Foundation www.kff.org\/medicare\/issue-brief\/changes-to-medicare-part-d-in-2024-and-2025-under-the-inflation-reduction-act-and-how-enrollees-will-benefit\/ (2023)."},{"key":"948_CR83","unstructured":"Dusetzina, S. B., Zuckerman, A. D., Keating, N. L. & Huskamp, H. A. Medicare Part D\u2019s new prescription payment plan may not reduce costs for all. Health Affairs www.healthaffairs.org\/content\/forefront\/medicare-part-d-s-new-prescription-payment-plan-may-not-reduce-costs-all (2024)."},{"key":"948_CR84","unstructured":"Doshi, J. A. & Niles, A. Smoothing Medicare Part D out-of-pocket costs under the Inflation Reduction Act. Health Affairs www.healthaffairs.org\/content\/forefront\/smoothing-part-d-out-pocket-costs-under-inflation-reduction-act (2023)."},{"key":"948_CR85","unstructured":"Kesselheim, A. S. Strategies that delay market entry of generic drugs. The Commonwealth Fund www.commonwealthfund.org\/publications\/journal-article\/2017\/sep\/strategies-delay-market-entry-generic-drugs (2017)."},{"key":"948_CR86","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1182\/blood-2015-11-680058","volume":"127","author":"GH Jones","year":"2016","unstructured":"Jones, G. H., Carrier, M. A., Silver, R. T. & Kantarjian, H. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. Blood 127, 1398\u20131402 (2016).","journal-title":"Blood"},{"key":"948_CR87","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1377\/hlthaff.2019.00673","volume":"39","author":"CV Dave","year":"2020","unstructured":"Dave, C. V., Sinha, M. S., Beall, R. F. & Kesselheim, A. S. Estimating the cost of delayed generic drug entry to Medicaid. Health Aff. 39, 1011\u20131017 (2020).","journal-title":"Health Aff."},{"key":"948_CR88","unstructured":"Liu, A. Drugmakers dig in their heels amid FTC\u2019s latest patent crackdown. What happens next? Fierce Pharma www.fiercepharma.com\/pharma\/drugmakers-dig-their-heels-amid-ftcs-latest-patent-challenges-what-could-come-next (2024)."},{"key":"948_CR89","unstructured":"Liu, A. FTC targets Novo\u2019s Ozempic, others in crackdown on 300-plus \u2018junk\u2019 patent listings in FDA database. Fierce Pharma www.fiercepharma.com\/pharma\/ftc-targets-novos-ozempic-others-crackdown-300-plus-junk-patent-listings-fda-database (2024)."},{"key":"948_CR90","unstructured":"Kansteiner, F. FTC eyes crackdown on improper drug patents in FDA\u2019s orange book. Fierce Pharma www.fiercepharma.com\/pharma\/ftc-takes-hardline-against-improper-listings-fdas-orange-book (2023)."},{"key":"948_CR91","unstructured":"Federal Trade Commission. FTC expands patent listing challenges targeting more than 300 junk listings for diabetes, weight loss, asthma and COPD drugs. Federal Trade Commission www.ftc.gov\/news-events\/news\/press-releases\/2024\/04\/ftc-expands-patent-listing-challenges-targeting-more-300-junk-listings-diabetes-weight-loss-asthma#:~:Text=Our%20mission%20is%20protecting%20the,Prescription%20Drugs (2024)."},{"key":"948_CR92","unstructured":"Warren, Jayapal push eight pharma companies to pull over 100 \u201csham\u201d patent listings, opening opportunity for more competition, lower drug prices. Elizabeth Warren www.warren.senate.gov\/newsroom\/press-releases\/warren-jayapal-push-eight-pharma-companies-to-pull-over-100-sham-patent-listings-opening-opportunity-for-more-competition-lower-drug-prices (2024)."},{"key":"948_CR93","unstructured":"Mansell, L. Reforms targeting \u201cpatent thickets\u201d would speed up the arrival of lower-cost drugs. Niskanen Center www.niskanencenter.org\/reforms-targeting-patent-thickets-would-speed-up-the-arrival-of-lower-cost-drugs\/ (2024)."},{"key":"948_CR94","unstructured":"I-MAK. Overpatented, overpriced. Curbing patent abuse: tackling the root of the drug pricing crisis. I-MAK www.i-mak.org\/wp-content\/uploads\/2023\/01\/Overpatented-Overpriced-2023-01-24.pdf (2022)."},{"key":"948_CR95","doi-asserted-by":"publisher","first-page":"lsac022","DOI":"10.1093\/jlb\/lsac022","volume":"9","author":"R Goode","year":"2022","unstructured":"Goode, R. & Chao, B. Biological patent thickets and delayed access to biosimilars, an American problem. J. Law Biosci. 9, lsac022 (2022).","journal-title":"J. Law Biosci."},{"key":"948_CR96","unstructured":"Becker, Z. Senate unanimously endorses legislation targeting pharma \u2018patent thickets\u2019. Fierce Pharma fiercepharma.com\/pharma\/senate-unanimously-signs-legislation-targeting-patent-thickets (2024)."},{"key":"948_CR97","unstructured":"I-MAK. America\u2019s overspend: how the pharmaceutical patent problem is fueling high drug prices. I-MAK www.i-mak.org\/wp-content\/uploads\/2017\/10\/Excess-Costs-Briefing-Paper-FINAL-2017-10-24-with-cover-rev.compressed.pdf (2017)."},{"key":"948_CR98","unstructured":"Senate passes Cornyn, Blumenthal bill to lower drug costs. John Cornyn United States Senator for Texas www.cornyn.senate.gov\/news\/senate-passes-cornyn-blumenthal-bill-to-lower-drug-costs\/ (2024)."},{"key":"948_CR99","doi-asserted-by":"publisher","first-page":"E668","DOI":"10.1001\/amajethics.2019.668","volume":"21","author":"MZ Zhai","year":"2019","unstructured":"Zhai, M. Z., Sarpatwari, A. & Kesselheim, A. S. Why are biosimilars not living up to their promise in the US? AMA J. Ethics 21, E668\u2013E678 (2019).","journal-title":"AMA J. Ethics"},{"key":"948_CR100","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.37765\/ajmc.2022.89188","volume":"28","author":"Q Liu","year":"2022","unstructured":"Liu, Q. Uptake of oncology biosimilars: managed care strategies to improve value-based care systems. Am. J. Manag. Care 28, S91\u2013S97 (2022).","journal-title":"Am. J. Manag. Care"},{"key":"948_CR101","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/hec.4471","volume":"31","author":"FG Frank","year":"2022","unstructured":"Frank, F. G., Shahzad, M., Kesselheim, A. S. & Feldman, W. Biosimilar competition: early learning. Health Econ. 31, 647\u2013663 (2022).","journal-title":"Health Econ."},{"key":"948_CR102","unstructured":"US Food and Drug Administration. Biosimilars action plan. FDA www.fda.gov\/drugs\/biosimilars\/biosimilars-action-plan (2024)."},{"key":"948_CR103","unstructured":"Samsung Bioepis. Biosimilar market report. 2nd edn, Q3 2023. Samsung Bioepis www.samsungbioepis.com\/upload\/attach\/SB+Biosimilar+Market+Report+Q3+2023.pdf (2023)."},{"key":"948_CR104","unstructured":"US Food and Drug Administration. FDA updates guidance on interchangeability. FDA www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-guidance-interchangeability (2024)."},{"key":"948_CR105","unstructured":"US Food and Drug Administration. 9 things to know about biosimilars and interchangeable biosimilars. FDA www.fda.gov\/drugs\/things-know-about\/9-things-know-about-biosimilars-and-interchangeable-biosimilars#:~:Text=Research%20by%20FDA%20has%20shown,approved%20as%20%22interchangeable%20biosimilars.%22 (2024)."},{"key":"948_CR106","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1001\/jama.2023.21481","volume":"330","author":"I Hernandez","year":"2023","unstructured":"Hernandez, I. et al. Reimbursement to pharmacies for generic drugs by Medicare Part D sponsors. JAMA 330, 2390\u20132392 (2023).","journal-title":"JAMA"},{"key":"948_CR107","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1001\/jamainternmed.2023.3932","volume":"184","author":"SB Dusetzina","year":"2024","unstructured":"Dusetzina, S. B. Medicare Part D payments for generic imatinib from 2017 to 2023. JAMA Intern. Med. 184, 104\u2013105 (2024).","journal-title":"JAMA Intern. Med."},{"key":"948_CR108","first-page":"1000317","volume":"13","author":"K Jenei","year":"2022","unstructured":"Jenei, K., Lythgoe, M. P. & Prasad, V. CostPlus and implications for generic imatinib. Lancet Reg. Health Am. 13, 1000317 (2022).","journal-title":"Lancet Reg. Health Am."},{"key":"948_CR109","unstructured":"US Federal Trade Commission. Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies (US Federal Trade Commission, 2024)."},{"key":"948_CR110","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1215\/03616878-10041107","volume":"47","author":"RE Sachs","year":"2022","unstructured":"Sachs, R. E., Jazowski, S. A., Gavulic, K. A., Donohue, J. M. & Dusetzina, S. B. Medicaid and accelerated approval: spending on drugs with and without proven clinical benefit. J. Health Polit. Policy Law 47, 673\u2013690 (2022).","journal-title":"J. Health Polit. Policy Law"},{"key":"948_CR111","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.4115","volume":"3","author":"RE Sachs","year":"2022","unstructured":"Sachs, R. E., Donohue, J. M. & Dusetzina, S. B. Reforming reimbursement for the US Food and Drug Administration\u2019s accelerated approval program to support state Medicaid programs. JAMA Health Forum 3, e224115 (2022).","journal-title":"JAMA Health Forum"},{"key":"948_CR112","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1056\/NEJMp2208954","volume":"387","author":"LA Fashoyin-Aje","year":"2022","unstructured":"Fashoyin-Aje, L. A., Mehta, G. U., Beaver, J. A. & Pazdur, R. The on- and off-ramps of oncology accelerated approval. N. Engl. J. Med. 387, 1439\u20131442 (2022).","journal-title":"N. Engl. J. Med."},{"key":"948_CR113","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.1158","volume":"3","author":"JJ Skydel","year":"2022","unstructured":"Skydel, J. J. et al. Spending by the Centers for Medicare & Medicaid Services before and after confirmation of benefit for drugs granted US Food and Drug Administration accelerated approval, 2012 to 2017. JAMA Health Forum 3, e221158 (2022).","journal-title":"JAMA Health Forum"},{"key":"948_CR114","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.3937","volume":"2","author":"BN Rome","year":"2021","unstructured":"Rome, B. N., Feldman, W. B. & Kesselheim, A. S. Medicare spending on drugs with accelerated approval, 2015-2019. JAMA Health Forum 2, e213937 (2021).","journal-title":"JAMA Health Forum"},{"key":"948_CR115","doi-asserted-by":"publisher","first-page":"938","DOI":"10.7326\/M21-4442","volume":"175","author":"J Ballreich","year":"2022","unstructured":"Ballreich, J. et al. Medicare spending on drugs with accelerated approval. Ann. Intern. Med. 175, 938\u2013944 (2022).","journal-title":"Ann. Intern. Med."},{"key":"948_CR116","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jamainternmed.2023.2381","volume":"183","author":"SA Jazowski","year":"2023","unstructured":"Jazowski, S. A., Vaidya, A. U., Donohue, J. M., Dusetzina, S. B. & Sachs, R. E. Commercial health plan and enrollee out-of-pocket spending on accelerated approval products in 2019. JAMA Intern. Med. 183, 1016\u20131018 (2023).","journal-title":"JAMA Intern. Med."},{"key":"948_CR117","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jama.2023.0625","volume":"329","author":"M Shahzad","year":"2023","unstructured":"Shahzad, M., Naci, H. & Wagner, A. K. Association between preapproval confirmatory trial initiation and conversion to traditional approval or withdrawal in the FDA accelerated approval pathway. JAMA 329, 760\u2013761 (2023).","journal-title":"JAMA"},{"key":"948_CR118","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jamainternmed.2023.0777","volume":"183","author":"SA Jazowski","year":"2023","unstructured":"Jazowski, S. A., Vaidya, A. U., Donohue, J. M., Dusetzina, S. B. & Sachs, R. E. Time to confirmatory study initiation after accelerated approval of cancer and noncancer drugs in the US. JAMA Intern. Med. 183, 737\u2013739 (2023).","journal-title":"JAMA Intern. Med."},{"key":"948_CR119","unstructured":"Fowler, L. & Mitta, V. CMS Innovation Center\u2019s one-year update on the executive order to lower prescription drug costs for Americans. CMS.gov www.cms.gov\/blog\/cms-innovation-centers-one-year-update-executive-order-lower-prescription-drug-costs-americans (2023)."},{"key":"948_CR120","unstructured":"Medicare Payment Advisory Commission. Addressing high prices of drugs covered under Medicare Part B. MedPAC www.medpac.gov\/wp-content\/uploads\/2023\/06\/Jun23_Ch1_MedPAC_Report_To_Congress_SEC.pdf (2023)."},{"key":"948_CR121","unstructured":"Longo, N. MedPAC proposal threatens access to medicines in Part B. PhRMA phrma.org\/en\/Blog\/MedPAC-proposal-threatens-access-to-medicines-in-Part-B (2023)."},{"key":"948_CR122","unstructured":"Serani, S. FDA\u2019s ODAC confronts issues with accelerated approval program. Targeted Oncology www.targetedonc.com\/view\/fda-s-odac-confronts-issues-with-accelerated-approval-program (2023)."},{"key":"948_CR123","unstructured":"Senate Republicans blast innovation-stifling drug-pricing model. Mike Crapo US Senator for Idaho www.crapo.senate.gov\/media\/newsreleases\/senate-republicans-blast-innovation-stifling-drug-pricing-model (2023)."}],"updated-by":[{"DOI":"10.1038\/s41571-024-00958-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000}}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00948-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00948-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00948-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T14:03:48Z","timestamp":1732025028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00948-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":123,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["948"],"URL":"https:\/\/doi.org\/10.1038\/s41571-024-00948-1","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41571-024-00958-z","asserted-by":"object"}]},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"19 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41571-024-00958-z","URL":"https:\/\/doi.org\/10.1038\/s41571-024-00958-z","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.B.D. is a member of the Institute for Clinical and Economic Review\u2019s (ICER) Midwestern Comparative Effectiveness Advisory Council and a member of the Medicare Payment Advisory Commission (MedPAC). This work does not necessarily represent the official position of ICER or MedPAC. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}